TScan Therapeutics paused its Phase 3 ALLOHA-2 study due to capital constraints and reorganized to prioritize advancing in vivo-engineered TCR-T candidates for solid tumors, amid maintaining cash runway into Q4 2027.
TScan Therapeutics paused its Phase 3 ALLOHA-2 study due to capital constraints and reorganized to prioritize advancing in vivo-engineered TCR-T candidates for solid tumors, amid maintaining cash runway into Q4 2027.